التفاصيل البيبلوغرافية
| العنوان: |
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. |
| المؤلفون: |
Martínez, Carmen1 (AUTHOR) cmarti@clinic.cat, Carpio, Cecilia2 (AUTHOR), Heras, Inmaculada3 (AUTHOR), Ríos-Herranz, Eduardo4 (AUTHOR), Buch, Joan5 (AUTHOR), Gutierrez, Antonio6 (AUTHOR), Romero, Samuel7 (AUTHOR), Zeberio, Izaskun8 (AUTHOR), García-García, Irene9 (AUTHOR), Rodriguez-Izquierdo, Antonia10 (AUTHOR), Alonso, Rosalía11 (AUTHOR), Bargay, Joan12 (AUTHOR), Barrenetxea, Cristina13 (AUTHOR), Domingo-Doménech, Eva14 (AUTHOR), de Haro, Manuel Espeso15 (AUTHOR), Palomera, Luis16 (AUTHOR), García-Sanz, Ramón17 (AUTHOR) |
| المصدر: |
Biology of Blood & Marrow Transplantation. Aug2020, Vol. 26 Issue 8, p1534-1542. 9p. |
| مصطلحات موضوعية: |
*HEMATOPOIETIC stem cell transplantation, *HODGKIN'S disease, *CANCER stem cells, *CLINICAL trial registries, *NATALIZUMAB, *PROGRESSION-free survival |
| مصطلحات جغرافية: |
SPAIN |
| مستخلص: |
• The efficacy and safety of nivolumab in real-life for the treatment of relapsed/refractory Hodgkin lymphoma are comparable to those reported in clinical trials. • The main reasons for nivolumab discontinuation were referral for transplantation and disease progression. • Based on a median follow-up of 18 months, our results show that consolidation with allogeneic hematopoietic stem cell transplantation is associated with favorable progression-free survival and overall survival. Clinical trials have shown that nivolumab has remarkable activity against relapsed/refractory classical Hodgkin lymphoma (cHL). However, the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation therapy in these patients remains controversial. We performed a retrospective analysis of data from 74 patients treated with nivolumab. The overall response rate was 58% (including 30.6% with complete responses). Treatment-related adverse events were reported in 56.8% of patients (grade ≥3 in 9.4%). The main reasons for nivolumab discontinuation were referral for transplantation (41.7% patients) and disease progression (37.5%). The 2-year overall survival (OS) rate was 52% for the entire series. Ultimately, 39 patients underwent allo-HSCT. The cumulative incidence of grade II-IV acute graft-versus-host disease was 33.3% (grade III-IV in 2 patients). The cumulative incidence of nonrelapse mortality was 13.2%. Among the patients who responded to nivolumab, the 2-year OS and progression-free survival (PFS) were higher in patients who underwent consolidation with allo-HSCT (77.5% versus 42.6% P =.126] and 73.9% versus 27.2% P =.025], respectively). Thus, the efficacy and safety of nivolumab were comparable to values reported in previous clinical trials. The percentage of patients who bridged to transplantation was high, indicating a preference for Spanish physicians. These results suggest that consolidation allo-HSCT increases OS and PFS. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder